{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T13:16:05Z","timestamp":1698844565954},"reference-count":53,"publisher":"Akademiai Kiado Zrt.","issue":"14","license":[{"start":{"date-parts":[[2021,4,4]],"date-time":"2021-04-04T00:00:00Z","timestamp":1617494400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["akjournals.com"],"crossmark-restriction":true},"short-container-title":["OH"],"published-print":{"date-parts":[[2021,4,4]]},"abstract":"<jats:p><jats:bold>\u00d6sszefoglal\u00f3.<\/jats:bold>\n                    <jats:italic>Bevezet\u00e9s:<\/jats:italic> Az id\u0151alku (time trade-off) egy nemzetk\u00f6zileg sz\u00e9les\n                    k\u00f6rben alkalmazott \u00e9letmin\u0151s\u00e9g- \u00e9s eg\u00e9szs\u00e9ghasznoss\u00e1g-m\u00e9r\u00e9si m\u00f3dszer. Az\n                    id\u0151alkuval m\u00e9rt hasznoss\u00e1g\u00e9rt\u00e9kek az eg\u00e9szs\u00e9g\u00fcgyi technol\u00f3gi\u00e1k\n                    k\u00f6lts\u00e9ghat\u00e9konys\u00e1gi vizsg\u00e1latakor az \u00e9letmin\u0151s\u00e9ggel korrig\u00e1lt \u00e9let\u00e9v\n                    (quality-adjusted life year, QALY) mutat\u00f3sz\u00e1m sz\u00e1m\u00edt\u00e1s\u00e1ra haszn\u00e1lhat\u00f3k. Kev\u00e9s\n                    ismerettel rendelkez\u00fcnk arr\u00f3l, hogy Magyarorsz\u00e1gon milyen betegs\u00e9gekben \u00e1llnak\n                    rendelkez\u00e9sre id\u0151alkuval m\u00e9rt hasznoss\u00e1g\u00e9rt\u00e9kek. <jats:italic>C\u00e9lkit\u0171z\u00e9s:<\/jats:italic>\n                    C\u00e9lunk szisztematikus irodalmi \u00e1ttekint\u00e9s keret\u00e9ben \u00f6sszefoglalni \u00e9s\n                    katalogiz\u00e1lni az id\u0151alku m\u00f3dszerrel m\u00e9rt hasznoss\u00e1g\u00e9rt\u00e9keket k\u00f6zl\u0151 publik\u00e1ci\u00f3kat\n                    Magyarorsz\u00e1gon. <jats:italic>M\u00f3dszer:<\/jats:italic> 2020 janu\u00e1rj\u00e1ban szisztematikus\n                    foly\u00f3irat-keres\u00e9st v\u00e9gezt\u00fcnk a PubMed, Web of Science \u00e9s Matarka elektronikus\n                    adatb\u00e1zisokban. Bev\u00e1logat\u00e1si krit\u00e9riumaink a k\u00f6vetkez\u0151k voltak: (1) eredeti\n                    k\u00f6zlem\u00e9nyek, melyek (2) id\u0151alku m\u00f3dszerrel m\u00e9rtek hasznoss\u00e1g\u00e9rt\u00e9ket, \u00e9s (3)\n                    magyarorsz\u00e1gi mint\u00e1n m\u00e9rt adatokat k\u00f6z\u00f6ltek. <jats:italic>Eredm\u00e9nyek:<\/jats:italic> 9\n                    eredeti k\u00f6zlem\u00e9nyt v\u00e1logattunk be, amelyek \u00f6sszesen 7 kr\u00f3nikus betegs\u00e9gben\n                    (Crohn-betegs\u00e9g, id\u0151skori maculadegeneratio, kr\u00f3nikus migr\u00e9n, pemphigus,\n                    psoriasis, primer dysmenorrhoea \u00e9s rheumatoid arthritis) 23 eg\u00e9szs\u00e9gi \u00e1llapot\n                    hasznoss\u00e1g\u00e1t hat\u00e1rozt\u00e1k meg. A kutat\u00e1sok mintanagys\u00e1ga 108 \u00e9s 1996 f\u0151 k\u00f6z\u00f6tt\n                    alakult. K\u00e9t kutat\u00e1s betegcsoportokat vizsg\u00e1lt, kett\u0151 az \u00e1ltal\u00e1nos popul\u00e1ci\u00f3t,\n                    \u00e9s h\u00e1rom vizsg\u00e1latban szerepelt mindkett\u0151. Hat kutat\u00e1s haszn\u00e1lta a hagyom\u00e1nyos\n                    id\u0151alku valamelyik form\u00e1j\u00e1t, egy pedig az \u00f6sszetett id\u0151alku m\u00f3dszert. Egy\n                    kutat\u00e1sban szerepelt \u2019rosszabb a hal\u00e1ln\u00e1l\u2019 v\u00e1laszlehet\u0151s\u00e9g. A leggyakrabban\n                    alkalmazott id\u0151t\u00e1v a standard 10 \u00e9v volt (71%). Az egyes \u00e1llapotok\n                    hasznoss\u00e1g\u00e1nak \u00e1tlaga 0,34 (kezeletlen pemphigus vulgaris) \u00e9s 0,94 (enyhe primer\n                    dysmenorrhoea) k\u00f6z\u00f6tt v\u00e1ltozott. A \u2019non-traderek\u2019 ar\u00e1nya az egyes kutat\u00e1sokban 0\n                    \u00e9s 29% k\u00f6z\u00f6tt v\u00e1ltozott. <jats:italic>K\u00f6vetkeztet\u00e9sek:<\/jats:italic> Egyre t\u00f6bb kr\u00f3nikus\n                    betegs\u00e9gben el\u00e9rhet\u0151k a magyar t\u00e1rsadalom vagy betegek preferenci\u00e1in alapul\u00f3\n                    eg\u00e9szs\u00e9ghasznoss\u00e1g-\u00e9rt\u00e9kek. A hazai id\u0151alku-vizsg\u00e1latok t\u00f6bbs\u00e9ge megfelel a\n                    nemzetk\u00f6zi min\u0151s\u00e9gi k\u00f6vetelm\u00e9nyeknek. Az id\u0151alku m\u00f3dszer alkalmaz\u00e1sa javasolt\n                    m\u00e1s kr\u00f3nikus \u00e1llapotokban is, a felm\u00e9rt hasznoss\u00e1g\u00e9rt\u00e9kek seg\u00edthetik az\n                    eg\u00e9szs\u00e9g\u00fcgyi technol\u00f3gi\u00e1kkal kapcsolatos finansz\u00edroz\u00f3i d\u00f6nt\u00e9shozatalt. Orv\n                    Hetil. 2021; 162(14): 542\u2013554.<\/jats:p>\n                <jats:p><jats:bold>Summary.<\/jats:bold>\n                    <jats:italic>Introduction:<\/jats:italic> Time trade-off (TTO) is a widely used method to\n                    assess health-related quality of life and health utilities for economic\n                    evaluations of health technologies. Little is known about the use of TTO in the\n                    Hungarian context. <jats:italic>Objective:<\/jats:italic> To systematically summarize the\n                    existing literature on the method in Hungary. <jats:italic>Method:<\/jats:italic> In\n                    January 2020, we conducted a systematic literature search in three electronic\n                    databases (MEDLINE, Web of Science and the Hungarian Periodicals Table of\n                    Contents Database). Our inclusion criteria were: (1) original publications,\n                    which (2) measured utilities by using TTO, (3) from a Hungarian sample.\n                        <jats:italic>Results:<\/jats:italic> Nine publications containing seven original\n                    studies were included that reported utilities for 23 different health states in\n                    seven chronic diseases (age-related macular degeneration, chronic migraine,\n                    Crohn\u2019s disease, pemphigus, primary dysmenorrhoea, psoriasis and rheumatoid\n                    arthritis). Sample sizes ranged from 108 to 1996 respondents. Two studies used\n                    general population samples, another two used patient groups and three studies\n                    used both. Six studies used a form of conventional TTO and one used composite\n                    TTO method. The most frequent timeframe was 10 years (71%). The lowest mean\n                    utility was 0.34 (uncontrolled pemphigus vulgaris), while the highest was 0.94\n                    (mild primary dysmenorrhoea). The overall proportion of non-traders ranged\n                    between 0 and 29% across studies. <jats:italic>Conclusions:<\/jats:italic> A growing number\n                    of studies are using TTO to assess utilities for chronic conditions from the\n                    general population or patients in Hungary. The majority of Hungarian TTO studies\n                    have met international quality standards. The assessment of TTO utilities is\n                    recommended also in other chronic conditions to assist health technology\n                    assessment. Orv Hetil. 2021; 162(14): 542\u2013554.<\/jats:p>","DOI":"10.1556\/650.2021.32056","type":"journal-article","created":{"date-parts":[[2021,4,5]],"date-time":"2021-04-05T04:16:05Z","timestamp":1617596165000},"page":"542-554","update-policy":"http:\/\/dx.doi.org\/10.1556\/policypage.crossmark.crossref.1","source":"Crossref","is-referenced-by-count":1,"title":["Eg\u00e9szs\u00e9ghasznoss\u00e1g-m\u00e9r\u00e9s id\u0151alku m\u00f3dszerrel Magyarorsz\u00e1gon"],"prefix":"10.1556","volume":"162","author":[{"given":"P\u00e9ter Gy\u00f6rgy","family":"Bal\u00e1zs","sequence":"first","affiliation":[{"name":"1 Budapesti Corvinus Egyetem, Eg\u00e9szs\u00e9g\u00fcgyi K\u00f6zgazdas\u00e1gtan Tansz\u00e9k, Budapest, F\u0151v\u00e1m t\u00e9r 8., 1093"},{"name":"2 Budapesti Corvinus Egyetem, Gazd\u00e1lkod\u00e1stani Doktori Iskola, Budapest"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentin","family":"Brodszky","sequence":"additional","affiliation":[{"name":"1 Budapesti Corvinus Egyetem, Eg\u00e9szs\u00e9g\u00fcgyi K\u00f6zgazdas\u00e1gtan Tansz\u00e9k, Budapest, F\u0151v\u00e1m t\u00e9r 8., 1093"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fanni","family":"Rencz","sequence":"additional","affiliation":[{"name":"1 Budapesti Corvinus Egyetem, Eg\u00e9szs\u00e9g\u00fcgyi K\u00f6zgazdas\u00e1gtan Tansz\u00e9k, Budapest, F\u0151v\u00e1m t\u00e9r 8., 1093"},{"name":"3 Magyar Tudom\u00e1nyos Akad\u00e9mia, Pr\u00e9mium Posztdoktori Kutat\u00f3i Program, Budapest"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"425","reference":[{"key":"ref0","unstructured":"1 James SL, Abate D, Abate KH, et al., GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 2018; 392(10159): 1789-1858. [Correction: Lancet 2019; 393(10190): e44.]"},{"key":"ref1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0167-6296(86)90020-2","article-title":"Measurement of health state utilities for economic appraisal: a review","volume":"5","author":"2 Torrance","year":"1986","unstructured":"2 Torrance GW. Measurement of health state utilities for economic appraisal: a review. J Health Econ. 1986; 5: 1-30.","journal-title":"J Health Econ"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/0021-9681(87)90019-1","article-title":"Utility approach to measuring health-related quality of life","volume":"40","author":"3 Torrance","year":"1987","unstructured":"3 Torrance GW. Utility approach to measuring health-related quality of life. J Chronic Dis. 1987; 40: 593-603.","journal-title":"J Chronic Dis"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"4 Tsevat J. What do utilities measure? Med Care 2000; 38(9 Suppl): II160-II164.","DOI":"10.1097\/00005650-200009002-00024"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"5 Brazier J, Ratcliffe J, Saloman J, et al. Measuring and valuing health benefits for economic evaluation. 2nd edn. Oxford University Press, 2016.","DOI":"10.1093\/med\/9780198725923.001.0001"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"6 Weinstein MC, Torrance G, McGuire A. QALYs: the basics. Value Health 2009; 12(Suppl 1): S5-S9.","DOI":"10.1111\/j.1524-4733.2009.00515.x"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"485","DOI":"10.2217\/cer.15.38","article-title":"Systematic overview of cost-effectiveness thresholds in ten countries across four continents","volume":"4","author":"7 Schwarzer","year":"2015","unstructured":"7 Schwarzer R, Rochau U, Saverno K, et al. Systematic overview of cost-effectiveness thresholds in ten countries across four continents. J Comp Eff Res. 2015; 4: 485-504.","journal-title":"J Comp Eff Res"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s40273-017-0544-y","article-title":"International regulations and recommendations for utility data for health technology assessment","volume":"35","author":"8 Rowen","year":"2017","unstructured":"8 Rowen D, Azzabi Zouraq I, Chevrou-Severac H, et al. International regulations and recommendations for utility data for health technology assessment. Pharmacoeconomics 2017; 35: 11-19.","journal-title":"Pharmacoeconomics"},{"key":"ref8","unstructured":"9 Ministry of Human Resources issued professional guideline for health technology assessment methodology of cost-effectiveness analyzes. [Az Emberi Er\u0151forr\u00e1sok Miniszt\u00e9riuma szakmai ir\u00e1nyelve az eg\u00e9szs\u00e9g\u00fcgyi technol\u00f3gia \u00e9rt\u00e9kel\u00e9s m\u00f3dszertan\u00e1r\u00f3l \u00e9s ennek keret\u00e9ben k\u00f6lts\u00e9ghat\u00e9konys\u00e1gi elemz\u00e9sek k\u00e9sz\u00edt\u00e9s\u00e9r\u0151l.] Eg\u00e9szs\u00e9g\u00fcgyi K\u00f6zl\u00f6ny 2017; LXVI(3): 821-840. [Hungarian]"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"2693","DOI":"10.1007\/s11136-016-1375-6","article-title":"EQ-5D in Central and Eastern Europe: 2000-2015","volume":"25","author":"10 Rencz","year":"2016","unstructured":"10 Rencz F, Gul\u00e1csi L, Drummond M, et al. EQ-5D in Central and Eastern Europe: 2000-2015. Qual Life Res. 2016; 25: 2693-2710.","journal-title":"Qual Life Res"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"11 Dolan P. Whose preferences count? Med Decis Making 1999; 19: 482-486.","DOI":"10.1177\/0272989X9901900416"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.jval.2019.01.004","article-title":"Identification, review, and use of health state utilities in cost-effectiveness models: an ISPOR Good Practices for Outcomes Research Task Force report","volume":"22","author":"12 Brazier","year":"2019","unstructured":"12 Brazier J, Ara R, Azzabi I, et al. Identification, review, and use of health state utilities in cost-effectiveness models: an ISPOR Good Practices for Outcomes Research Task Force report. Value Health 2019; 22: 267-275.","journal-title":"Value Health"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1258\/135581904322716111","article-title":"Roughly right or precisely wrong? Systematic review of quality-of-life weights elicited with the time trade-off method","volume":"9","author":"Arnesen T","year":"2004","unstructured":"13 Arnesen T, Trommald M. Roughly right or precisely wrong? Systematic review of quality-of-life weights elicited with the time trade-off method. J Health Serv Res Policy 2004; 9: 43-50.","journal-title":"J Health Serv Res Policy"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1002\/hec.895","article-title":"Are QALYs based on time trade-off comparable? - A systematic review of TTO methodologies","volume":"14","author":"Arnesen T","year":"2005","unstructured":"14 Arnesen T, Trommald M. Are QALYs based on time trade-off comparable? - A systematic review of TTO methodologies. Health Econ. 2005; 14: 39-53.","journal-title":"Health Econ"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/0168-8510(90)90421-9","article-title":"EuroQol - a new facility for the measurement of health-related quality of life","volume":"16","author":"EuroQol Group","year":"1990","unstructured":"15 EuroQol Group. EuroQol - a new facility for the measurement of health-related quality of life. Health Policy (Amsterdam) 1990; 16: 199-208.","journal-title":"Health Policy (Amsterdam)"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1007\/s10198-020-01195-8","article-title":"Which multi-attribute utility instruments are recommended for use in cost-utility analysis? A review of national health technology assessment (HTA) guidelines","volume":"21","author":"16 Kennedy-Martin","year":"2020","unstructured":"16 Kennedy-Martin M, Slaap B, Herdman M, et al. Which multi-attribute utility instruments are recommended for use in cost-utility analysis? A review of national health technology assessment (HTA) guidelines. Eur J Health Econ. 2020; 21: 1245-1257.","journal-title":"Eur J Health Econ"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1016\/j.jval.2020.03.019","article-title":"Parallel valuation of the EQ-5D-3L and EQ-5D-5L by time trade-off in Hungary","volume":"23","author":"17 Rencz","year":"2020","unstructured":"17 Rencz F, Brodszky V, Gul\u00e1csi L, et al. Parallel valuation of the EQ-5D-3L and EQ-5D-5L by time trade-off in Hungary. Value Health 2020; 23: 1235-1245.","journal-title":"Value Health"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.jval.2010.10.015","article-title":"Utility values in National Institute for Health and Clinical Excellence (NICE) technology appraisals","volume":"14","author":"18 Tosh","year":"2011","unstructured":"18 Tosh JC, Longworth LJ, George E. Utility values in National Institute for Health and Clinical Excellence (NICE) technology appraisals. Value Health 2011; 14: 102-109.","journal-title":"Value Health"},{"key":"ref18","unstructured":"19 Borsi A. The valuation of the Hungarian quality of life using EQ-5D method. [Magyar \u00e9letmin\u0151s\u00e9g \u00e9rt\u00e9kek felm\u00e9r\u00e9se az EQ-5D m\u00f3dszer seg\u00edts\u00e9g\u00e9vel.] IME 2012; 11: 30-33. [Hungarian]"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"20 Po\u00f3r AK, S\u00e1rdy M, Cserni T, et al. Assessment of health-related quality of life in psoriasis patients in Hungary. [Psoriasisban szenved\u0151 betegek \u00e9letmin\u0151s\u00e9g\u00e9nek vizsg\u00e1lata Magyarorsz\u00e1gon.] Orv Hetil. 2018; 159: 837-846. [Hungarian]","DOI":"10.1556\/650.2018.31061"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"21 Farkas K, Kolossv\u00e1ry E, J\u00e1rai Z. Cilostazol improves the quality of life and lower-limb functional capacity also in diabetic patients. [A cilostazol diabeteses betegekben is jav\u00edtja az \u00e9letmin\u0151s\u00e9get \u00e9s az als\u00f3 v\u00e9gtagi funkcion\u00e1lis kapacit\u00e1st.] Orv Hetil. 2020; 161: 1637-1645. [Hungarian]","DOI":"10.1556\/650.2020.31969"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"22 Tam\u00e1si L, Speer G. Assessment of patient-reported outcomes by questionnaires in patients with Moderate and severe chronic obstructive pulmonary disease treated with glycopyrroniUm in the reaL lifE setTing in Hungary (AMULET). [Glikopirr\u00f3niummal kezelt k\u00f6z\u00e9ps\u00falyos \u00e9s s\u00falyos kr\u00f3nikus obstrukt\u00edv t\u00fcd\u0151betegek \u00e1llapot\u00e1nak k\u00e9rd\u0151\u00edves \u00e9rt\u00e9kel\u00e9se val\u00f3s k\u00f6r\u00fclm\u00e9nyek k\u00f6z\u00f6tt. AMULET-vizsg\u00e1lat.] Orv Hetil. 2020; 161: 295-305. [Hungarian]","DOI":"10.1556\/650.2020.31661"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"23 Bohner-Beke A, K\u0151nign\u00e9 P\u00e9ter A, Vass L, et al. Hungarian validation of the clubfoot disease-specific instrument. [Dongal\u00e1b-specifikus \u00e9letmin\u0151s\u00e9g-k\u00e9rd\u0151\u00edv magyar adapt\u00e1ci\u00f3ja.] Orv Hetil. 2018; 159: 1269-1277. [Hungarian]","DOI":"10.1556\/650.2018.31115"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"24 Boye KS, Matza LS, Feeny DH, et al. Challenges to time trade-off utility assessment methods: when should you consider alternative approaches? Expert Rev Pharmacoecon Outcomes Res. 2014; 14: 437-450.","DOI":"10.1586\/14737167.2014.912562"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"25 Attema AE, Edelaar-Peeters Y, Versteegh MM, et al. Time trade-off: one methodology, different methods. Eur J Health Econ. 2013; 14(Suppl 1): S53-S64.","DOI":"10.1007\/s10198-013-0508-x"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1177\/0272989X13480852","article-title":"Comparing EQ-5D valuation studies: a systematic review and methodological reporting checklist","volume":"34","author":"26 Xie","year":"2014","unstructured":"26 Xie F, Gaebel K, Perampaladas K, et al. Comparing EQ-5D valuation studies: a systematic review and methodological reporting checklist. Med Decis Making 2014; 34: 8-20.","journal-title":"Med Decis Making"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s10198-013-0503-2","article-title":"Introducing the composite time trade-off: a test of feasibility and face validity","volume":"14","author":"27 Janssen","year":"2013","unstructured":"27 Janssen BM, Oppe M, Versteegh MM, et al. Introducing the composite time trade-off: a test of feasibility and face validity. Eur J Health Econ. 2013; 14: 5-13.","journal-title":"Eur J Health Econ"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"713","DOI":"10.2165\/11317060-000000000-00000","article-title":"Methods for measuring temporary health states for cost-utility analyses","volume":"27","author":"28 Wright","year":"2009","unstructured":"28 Wright DR, Wittenberg E, Swan JS, et al. Methods for measuring temporary health states for cost-utility analyses. Pharmacoeconomics 2009; 27: 713-723.","journal-title":"Pharmacoeconomics"},{"key":"ref28","doi-asserted-by":"publisher","unstructured":"29 van Nooten F, Busschbach J, van Agthoven M, et al. What should we know about the person behind a TTO? Eur J Health Econ. 2018; 19: 1207-1211.","DOI":"10.1007\/s10198-018-0975-1"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1007\/s11136-019-02121-z","article-title":"Patterns, trends and methodological associations in the measurement and valuation of childhood health utilities","volume":"28","author":"30 Kwon","year":"2019","unstructured":"30 Kwon J, Kim SW, Ungar WJ, et al. Patterns, trends and methodological associations in the measurement and valuation of childhood health utilities. Qual Life Res. 2019; 28: 1705-1724.","journal-title":"Qual Life Res"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1007\/s40273-014-0168-4","article-title":"The better than dead method: feasibility and interpretation of a valuation study","volume":"32","author":"31 van Hoorn","year":"2014","unstructured":"31 van Hoorn RA, Donders AR, Oppe M, et al. The better than dead method: feasibility and interpretation of a valuation study. Pharmacoeconomics 2014; 32: 789-799.","journal-title":"Pharmacoeconomics"},{"key":"ref31","doi-asserted-by":"publisher","unstructured":"32 Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement. PLoS Med. 2009; 6: e1000097.","DOI":"10.1371\/journal.pmed.1000097"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1017\/S0266462317000897","article-title":"Performance of Ovid MEDLINE search filters to identify health state utility studies","volume":"33","author":"33 Arber","year":"2017","unstructured":"33 Arber M, Garcia S, Veale T, et al. Performance of Ovid MEDLINE search filters to identify health state utility studies. Int J Technol Assess Health Care 2017; 33: 472-480.","journal-title":"Int J Technol Assess Health Care"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"2106","DOI":"10.1111\/jdv.15765","article-title":"Patient-assigned health utility values for controlled and uncontrolled pemphigus vulgaris and foliaceus","volume":"33","author":"34 Hajdu","year":"2019","unstructured":"34 Hajdu K, Brodszky V, Stalmeier PF, et al. Patient-assigned health utility values for controlled and uncontrolled pemphigus vulgaris and foliaceus. J Eur Acad Dermatol Venereol. 2019; 33: 2106-2113.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref34","doi-asserted-by":"publisher","unstructured":"35 Inotai A, Rojkovich B, F\u00fcl\u00f6p A, et al. Health-related quality of life and utility in patients receiving biological and non-biological treatments in rheumatoid arthritis. Rheumatol Int. 2012","DOI":"10.1007\/s00296-010-1721-x"},{"key":"ref35","unstructured":"32: 963-969. [Epub 2011 Jan 18]"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1186\/s12877-017-0619-9","article-title":"Subjective health expectations of patients with age-related macular degeneration treated with antiVEGF drugs","volume":"17","author":"36 P\u00e9ntek","year":"2017","unstructured":"36 P\u00e9ntek M, Brodszky V, B\u00edr\u00f3 Z, et al. Subjective health expectations of patients with age-related macular degeneration treated with antiVEGF drugs. BMC Geriatr. 2017; 17: 233.","journal-title":"BMC Geriatr"},{"key":"ref37","doi-asserted-by":"publisher","unstructured":"37 Po\u00f3r AK, Brodszky V, P\u00e9ntek M, et al. Is the DLQI appropriate for medical decision-making in psoriasis patients? Arch Dermatol Res. 2018; 310: 47-55.","DOI":"10.1007\/s00403-017-1794-4"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1007\/s11136-015-1208-z","article-title":"Discrepancies between the Dermatology Life Quality Index and utility scores","volume":"25","author":"38 Rencz","year":"2016","unstructured":"38 Rencz F, Baji P, Gul\u00e1csi L, et al. Discrepancies between the Dermatology Life Quality Index and utility scores. Qual Life Res. 2016; 25: 1687-1696.","journal-title":"Qual Life Res"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s10072-014-1920-4","article-title":"Health state utilities for migraine based on attack frequency: a time trade-off study","volume":"36","author":"39 Rencz","year":"2015","unstructured":"39 Rencz F, Brodszky V, P\u00e9ntek M, et al. Health state utilities for migraine based on attack frequency: a time trade-off study. Neurol Sci. 2015; 36: 197-202.","journal-title":"Neurol Sci"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1097\/j.pain.0000000000001028","article-title":"Bleeding out the quality-adjusted life years: evaluating the burden of primary dysmenorrhea using time trade-off and willingness-to-pay methods","volume":"158","author":"40 Rencz","year":"2017","unstructured":"40 Rencz F, P\u00e9ntek M, Stalmeier PF, et al. Bleeding out the quality-adjusted life years: evaluating the burden of primary dysmenorrhea using time trade-off and willingness-to-pay methods. Pain 2017; 158: 2259-2267.","journal-title":"Pain"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s10198-019-01065-y","article-title":"Patient and general population values for luminal and perianal fistulising Crohn's disease health states","volume":"20","author":"41 Rencz","year":"2019","unstructured":"41 Rencz F, Stalmeier PF, P\u00e9ntek M, et al. Patient and general population values for luminal and perianal fistulising Crohn's disease health states. Eur J Health Econ. 2019; 20: 91-100.","journal-title":"Eur J Health Econ"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1111\/bjd.14647","article-title":"Valuation of pemphigus vulgaris and pemphigus foliaceus health states: a convenience sample experiment","volume":"175","author":"42 Rencz","year":"2016","unstructured":"42 Rencz F, Brodszky V, Stalmeier PF, et al. Valuation of pemphigus vulgaris and pemphigus foliaceus health states: a convenience sample experiment. Br J Dermatol. 2016; 175: 593-599.","journal-title":"Br J Dermatol"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1023\/A:1026600428484","article-title":"Health-related quality of life in patients with Crohn's disease: influence of surgical operation - prospective trial","volume":"44","author":"43 Tillinger","year":"1999","unstructured":"43 Tillinger W, Mittermaier C, Lochs H, et al. Health-related quality of life in patients with Crohn's disease: influence of surgical operation - prospective trial. Dig Dis Sci. 1999; 44: 932-938.","journal-title":"Dig Dis Sci"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1097\/MEG.0000000000001031","article-title":"Quality of life related to oral, subcutaneous, and intravenous biologic treatment of inflammatory bowel disease: a time trade-off study","volume":"30","author":"44 Holko","year":"2018","unstructured":"44 Holko P, Kawalec P, Mossakowska M. Quality of life related to oral, subcutaneous, and intravenous biologic treatment of inflammatory bowel disease: a time trade-off study. Eur J Gastroenterol Hepatol. 2018; 30: 174-180.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1007\/s40273-019-00811-7","article-title":"Valuation of EQ-5D-5L health states in Poland: the first EQ-VT-based study in Central and Eastern Europe","volume":"37","author":"45 Golicki","year":"2019","unstructured":"45 Golicki D, Jakubczyk M, Graczyk K, et al. Valuation of EQ-5D-5L health states in Poland: the first EQ-VT-based study in Central and Eastern Europe. Pharmacoeconomics 2019; 37: 1165-1176.","journal-title":"Pharmacoeconomics"},{"key":"ref46","doi-asserted-by":"publisher","unstructured":"46 Olariu E, Paveliu MS, Baican E, et al. Measuring health-related quality of life in the general population and Roma communities in Romania: study protocol for two cross-sectional studies. BMJ Open 2019; 9: e029067.","DOI":"10.1136\/bmjopen-2019-029067"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"8","DOI":"10.2478\/sjph-2020-0002","article-title":"Valuation of EQ-5D-3l health states in Slovenia: VAS based and TTO based value sets","volume":"59","author":"47 Prevolnik Rupel","year":"2020","unstructured":"47 Prevolnik Rupel V, Srakar A, Rand K. Valuation of EQ-5D-3l health states in Slovenia: VAS based and TTO based value sets. Slovenian J Public Health. 2020; 59: 8-17.","journal-title":"Slovenian J Public Health"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1111\/j.1524-4733.2009.00596.x","article-title":"Valuation of EQ-5D health states in Poland: first TTO-based social value set in Central and Eastern Europe","volume":"13","author":"48 Golicki","year":"2010","unstructured":"48 Golicki D, Jakubczyk M, Niewada M, et al. Valuation of EQ-5D health states in Poland: first TTO-based social value set in Central and Eastern Europe. Value Health 2010; 13: 289-297.","journal-title":"Value Health"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1186\/s12955-018-0994-8","article-title":"Systematic review of health state utility values in metastatic non-small cell lung cancer with a focus on previously treated patients","volume":"16","author":"49 Paracha","year":"2018","unstructured":"49 Paracha N, Abdulla A, MacGilchrist KS. Systematic review of health state utility values in metastatic non-small cell lung cancer with a focus on previously treated patients. Health Qual Life Outcomes 2018; 16: 179.","journal-title":"Health Qual Life Outcomes"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1177\/0272989X09357475","article-title":"Protocols for time trade-off valuations of health states worse than dead: a literature review and conceptual framework for systematic analysis","volume":"30","author":"50 Tilling","year":"2010","unstructured":"50 Tilling C, Devlin N, Tsuchiya A, et al. Protocols for time trade-off valuations of health states worse than dead: a literature review and conceptual framework for systematic analysis. Med Decis Making 2010; 30: 610-619.","journal-title":"Med Decis Making"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1007\/s40273-016-0429-5","article-title":"Using best-worst scaling to investigate preferences in health care","volume":"34","author":"51 Cheung","year":"2016","unstructured":"51 Cheung KL, Wijnen BF, Hollin IL, et al. Using best-worst scaling to investigate preferences in health care. Pharmacoeconomics 2016; 34: 1195-1209.","journal-title":"Pharmacoeconomics"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/s40273-018-0734-2","article-title":"Discrete choice experiments in health economics: past, present and future","volume":"37","author":"52 Soekhai","year":"2019","unstructured":"52 Soekhai V, de Bekker-Grob EW, Ellis AR, et al. Discrete choice experiments in health economics: past, present and future. Pharmacoeconomics 2019; 37: 201-226.","journal-title":"Pharmacoeconomics"}],"container-title":["Orvosi Hetilap"],"original-title":[],"link":[{"URL":"https:\/\/akjournals.com\/view\/journals\/650\/162\/14\/article-p542.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/akjournals.com\/downloadpdf\/journals\/650\/162\/14\/article-p542.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T13:48:12Z","timestamp":1698760092000},"score":1,"resource":{"primary":{"URL":"https:\/\/akjournals.com\/view\/journals\/650\/162\/14\/article-p542.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,4]]},"references-count":53,"journal-issue":{"issue":"14"},"URL":"https:\/\/doi.org\/10.1556\/650.2021.32056","relation":{},"ISSN":["0030-6002","1788-6120"],"issn-type":[{"value":"0030-6002","type":"print"},{"value":"1788-6120","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,4]]}}}